CRANBURY, N.J., July 31, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Thursday, August 7, 2014 at 5:00 p.m. ET to discuss financial results for the second quarter ended June 30, 2014.
The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call at 5:00 p.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).
A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.A telephonic replay of the call will be available for seven days beginning at 8:00 p.m. ET on August 7, 2014. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 74809147. About Amicus Therapeutics Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS-1. FOLD-G
CONTACT: Investors: Amicus Therapeutics Chip Baird Chief Financial Officer firstname.lastname@example.org (609) 662-2063 Media: Pure Communications Dan Budwick email@example.com (973) 271-6085